Athira Pharma to Participate in Upcoming May Investor Conferences
May 08, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 25, 2023 16:01 ET
|
Athira Pharma, Inc.
Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer’s disease Preclinical findings with...
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 11, 2023 07:00 ET
|
Athira Pharma, Inc.
Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients including improvements in measures of cognition and...
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023 01:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., March 28, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
March 23, 2023 16:05 ET
|
Athira Pharma, Inc.
On track to complete enrollment in Phase 2/3 LIFT-AD trial of fosgonimeton for mild-to-moderate Alzheimer’s disease in mid-2023 with topline data in early 2024 Continuing to advance development...
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
March 08, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., March 08, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., March 06, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
February 01, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 31, 2023 07:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023 07:00 ET
|
Athira Pharma, Inc.
Advancing small molecule therapeutic candidates with clinical and preclinical data suggesting potential neuroprotective, neurotrophic, procognitive and disease-modifying effects Fosgonimeton Phase...